HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 34/3/616    most recent 09031936.00070808v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Klagas, I. Articles by Roth, M. PubMed PubMed Citation Articles by Klagas, I. Articles by Roth, M.

Decreased hyaluronan in airway smooth muscle cells from patients with asthma and COPD

¹ Dept Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. ² Pulmonary Cell Research, Dept Research, University Hospital Basel, Basel, Switzerland. ³ Dept Pharmacology, University of Sydney, and ⁴ The Woolcock Institute for Medical Research, Sydney, Australia. ⁵ Both authors contributed equally to this work.

CORRESPONDENCE: E. Papakonstantinou, Dept Pharmacology, School of Medicine, Aristotle University of Thessaloniki 54124, Thessaloniki, Greece. E-mail: epap{at}med.auth.gr

Keywords: Airway smooth muscle cells, asthma, CD44, chronic obstructive pulmonary disease, glycosaminoglycans, hyaluronic acid

Received: May 8, 2008
Accepted February 24, 2009

Glycosaminoglycans (GAG) are essential extracellular matrix molecules which regulate tissue flexibility, a parameter that is reduced in airways of patients with asthma and chronic obstructive pulmonary disease (COPD). We investigated the expression of GAG and their metabolising enzymes in primary human airway smooth muscle cells (ASMC) obtained from healthy donors (controls) and patients with asthma or COPD.

Total GAG synthesis was assessed by [³H]-glucosamine incorporation. GAG were isolated, purified, fractionated by electrophoresis and characterised using specific GAG-degrading enzymes. Secretion of hyaluronic acid (HA) by ASMC from patients with asthma or COPD was significantly decreased compared with controls. RT-PCR analysis and western blotting revealed that this decrease was associated with a significant reduction in the expression of HA synthase-1 and -2 and a significant increase of hyaluronidase-1. Furthermore, the expression of the HA receptor CD44 was significantly decreased, whereas the receptor for HA-mediated motility was not expressed in asthma or COPD.

Our results indicate that there is a decreased expression of HA in asthma and COPD associated with a synergistic regulation of HA metabolising enzymes that may regulate the pathological airway remodelling in these lung diseases.